ASH: Servier unveils full dataset for Tibsovo in specific AML mutations, and the FDA appears a stone's throw away
Back in August, Servier revealed that a Phase III study for Tibsovo saw results so efficacious that investigators recommended stopping the trial early. Now at ASH, observers are getting a view at what exactly caused the halt.
Looking at Tibsovo in combination with chemo compared to placebo and chemo, Servier reported Saturday that their drug combination resulted in statistically significant improvements in event-free survival and overall survival. The p-values came in solid as well, with Tibsovo notching values of p=0.0011 and p=0.0005 for each of the respective measures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.